

Appl. No. 10/553,695

Response dated February 12, 2010

Reply to Office action of November 9, 2009

**AMENDMENTS TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1 - 29. (Cancelled)

30. (Currently amended) A method of activating NKT cells, which method comprises administering to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R<sup>5</sup> represents R<sup>51</sup>, R<sup>52</sup> or R<sup>53</sup>; and R<sup>6</sup> represents hydrogen, R<sup>62</sup>, R<sup>63</sup>, R<sup>64</sup>, or R<sup>65</sup>:

Appl. No. 10/553,695


Response dated February 12, 2010

Reply to Office action of November 9, 2009


R<sup>51</sup> :




R<sup>52</sup> :




R<sup>53</sup> :




R<sup>62</sup> :




R<sup>64</sup> :



R<sup>63</sup> :



R<sup>65</sup> :




said administering resulting in activation of NKT cells in

the mammal.

31. (Cancelled)


32. (Currently amended) A method of accelerating IL-4 production, which method comprises administering to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R<sup>5</sup> represents R<sup>51</sup>, R<sup>52</sup> or R<sup>53</sup>; and R<sup>6</sup> represents hydrogen, R<sup>62</sup>, R<sup>63</sup>, R<sup>64</sup>, or R<sup>65</sup>:


R<sup>51</sup>:




R<sup>52</sup>:




R<sup>53</sup>:




R<sup>62</sup> :




R<sup>64</sup> :



R<sup>63</sup> :



R<sup>65</sup> :




said administering resulting in accelerating IL-4 production in the mammal.

33. (Cancelled)


34. (Currently amended) A method of accelerating IFN- $\gamma$  production, which method comprises administering to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3) :  
formula (3)

Appl. No. 10/553,695  
Response dated February 12, 2010  
Reply to Office action of November 9, 2009




wherein R<sup>5</sup> represents R<sup>51</sup>, R<sup>52</sup> or R<sup>53</sup>; and R<sup>6</sup> represents hydrogen, R<sup>62</sup>, R<sup>63</sup>, R<sup>64</sup>, or R<sup>65</sup>:


R<sup>51</sup>:




R<sup>52</sup>:




R<sup>53</sup>:




R<sup>62</sup> :




R<sup>64</sup> :



R<sup>63</sup> :



R<sup>65</sup> :



said administering resulting in accelerating IFN- $\gamma$

production in the mammal.

35 - 59. (Cancelled)

60. (New) The method of claim 30, wherein said cell activator is administered by intravenous injection, infusion, oral ingestion, or intraperitoneal injection.

61. (New) The method of claim 32 wherein said cell activator is administered by intravenous injection, infusion, oral ingestion, or intraperitoneal injection.

62. (New) The method of claim 34, wherein said cell activator is administered by intravenous injection, infusion, oral ingestion, or intraperitoneal injection.